ANI Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 5/6
ANI Pharmaceuticals possède un total de capitaux propres de $480.6M et une dette totale de $285.2M, ce qui porte son ratio d'endettement à 59.4%. Son actif total et son passif total sont $920.8M et de $440.1M. L'EBIT de ANI Pharmaceuticals est $48.2M ce qui fait que son ratio de couverture des intérêts 2.3. Elle dispose de liquidités et de placements à court terme de $247.1M.
Informations clés
59.4%
Ratio d'endettement
US$285.24m
Dette
| Ratio de couverture des intérêts | 2.3x |
| Argent liquide | US$247.05m |
| Fonds propres | US$480.61m |
| Total du passif | US$440.14m |
| Total des actifs | US$920.75m |
Mises à jour récentes de la santé financière
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28Recent updates
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05Analyse de la situation financière
Passif à court terme: Les actifs à court terme de ANIP ( $555.5M ) dépassent ses passifs à court terme ( $140.0M ).
Passif à long terme: Les actifs à court terme de ANIP ( $555.5M ) dépassent ses passifs à long terme ( $300.2M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de ANIP ( 7.9% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de ANIP a été réduit de 92.5% à 59.4% au cours des 5 dernières années.
Couverture de la dette: La dette de ANIP est bien couverte par le flux de trésorerie opérationnel ( 39.5% ).
Couverture des intérêts: Les paiements d'intérêts de ANIP sur sa dette ne sont pas bien couverts par l'EBIT ( 2.3 x couverture).